Kimberly-Clark Points Downward on Suzano Hookup
Shares in Kimberly-Clark (NASDAQ:KMB) slumped on Thursday after the Kleenex tissue maker struck a deal with Brazilian pulp maker Suzano to sell a majority stake in its international tissue business, valuing the business at about $3.4 billionThe deal, structured as a strategic partnership, will form a new joint venture in which Kimberly-Clark would own a 49% stake, while Suzano would own the rest.The Brazilian company will pay Kimberly-Clark about $1.73 billion in cash for the 51% stake at the closing of the transaction, which is expected in mid-2026.Suzano will have the option to purchase Kimberly-Clark’s ownership interest at certain specified times and subject to certain conditions, the Irving, Texas-based company said.Kimberly-Clark, which has been struggling with weak sales, has been taking efforts to reorganize its businesses to simplify operations and cut costs as it looks to focus on more profitable parts such as personal care and North America tissue segments.The combined business entity would be incorporated in the Netherlands and include 22 manufacturing facilities located in 14 regions, such as Europe, Asia, the Middle East and Central America.As part of the new joint venture, Kimberly-Clark will retain its consumer tissue and professional businesses in the U.S. and its interests in existing joint ventures in Mexico, South Korea and Bahrain, among other countries.KMB shares tumbled $3.77, or 2.7%, to $134.66.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


